RecruitingPHASE1, PHASE2NCT05874414

Combination of GNS561 and Trametinib in Patients With Advanced KRAS Mutated Cholangiocarcinoma

Studying Cholangiocarcinoma

Last synced from ClinicalTrials.gov April 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Genfit
Principal Investigator: Peter Lichten, M.D.
Genfit
Intervention: GNS561 + Trametinib(drug)
Enrollment: 74 target
Eligibility: 18 years · All sexes
Timeline: 2023 – 2026

Study locations (11)

USC Norris Comprehensive Cancer Center, Los Angeles, California, United States
LA Cancer Network, Los Angeles, California, United States
Orlando Health, Orlando, Florida, United States
Moffitt Cancer Center, Tampa, Florida, United States
University Of Chicago Medical Center, Chicago, Illinois, United States
Roswell Park Cancer Institute, Buffalo, New York, United States
Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
University of Texas, MD Anderson Cancer Center, Houston, Texas, United States
University of Virginia Comprehensive Cancer Center, Charlottesville, Virginia, United States
Froedtert Hospital and the Medical College of Wisconsin, Milwaukee, Wisconsin, United States
Pan American Center for Oncology Trials, LLC, Rio Piedras, Puerto Rico, Puerto Rico

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05874414 on ClinicalTrials.gov

Other trials for Cholangiocarcinoma

Additional recruiting or active studies for the same condition.

See all trials for Cholangiocarcinoma →

← Back to all trials